Elaine Johnstone

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. pmc Trial Protocol: Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact of communication upon adherence
    Theresa M Marteau
    Psychology Department at Guy s, Health Psychology Section, King s College London, 5th floor Bermondsey Wing, Guy s Campus, London SE1 9RT, UK
    BMC Public Health 10:680. 2010
  2. ncbi Determinants of the rate of nicotine metabolism and effects on smoking behavior
    Elaine Johnstone
    Department of Clinical Pharmacology, Cancer Research UK Medical Statistics Group, Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom
    Clin Pharmacol Ther 80:319-30. 2006
  3. ncbi Zyban for smoking cessation in a general practice setting: the response to an invitation to make a quit attempt
    Elaine Johnstone
    Cancer Research UK General Practice Research Group, Clinical Pharmacology, Oxford University, UK
    Addict Biol 9:227-32. 2004
  4. ncbi The dopamine D2 receptor C32806T polymorphism (DRD2 Taq1A RFLP) exhibits no association with smoking behaviour in a healthy UK population
    E C Johnstone
    Cancer Research UK, General Practice Research Group, University of Oxford Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford, UK
    Addict Biol 9:221-6. 2004
  5. ncbi Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch
    Elaine C Johnstone
    Cancer Research UK General Practice Research Group, Department of Clinical Pharmacology, University of Oxford, Oxford, UK
    Pharmacogenetics 14:83-90. 2004
  6. doi Role of rare variants in undetermined multiple adenomatous polyposis and early-onset colorectal cancer
    Jeremie H Lefevre
    Department of Clinical Pharmacology, Cancer and Immunogenetics Laboratory, University of Oxford, Oxford, UK
    J Hum Genet 57:709-16. 2012
  7. pmc Weekly versus basic smoking cessation support in primary care: a randomised controlled trial
    Paul Aveyard
    Cancer Research UK General Practice Research Group, Department of Clinical Pharmacology, University of Oxford, Oxford, UK
    Thorax 62:898-903. 2007
  8. ncbi The genetic basis for smoking behavior: a systematic review and meta-analysis
    Marcus Munafo
    Department of Clinical Pharmacology, University of Oxford, UK
    Nicotine Tob Res 6:583-97. 2004
  9. pmc Use of multivariate analysis to suggest a new molecular classification of colorectal cancer
    Enric Domingo
    Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, UK
    J Pathol 229:441-8. 2013
  10. pmc Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial
    Patricia Yudkin
    Department of Primary Health Care, University of Oxford, Oxford OX3 7LF
    BMJ 328:989-90. 2004

Collaborators

Detail Information

Publications28

  1. pmc Trial Protocol: Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact of communication upon adherence
    Theresa M Marteau
    Psychology Department at Guy s, Health Psychology Section, King s College London, 5th floor Bermondsey Wing, Guy s Campus, London SE1 9RT, UK
    BMC Public Health 10:680. 2010
    ..II Amongst smokers who fail to quit at six months, motivation to make another quit attempt is lower when informed that their oral dose of NRT was tailored to genotype rather than phenotype...
  2. ncbi Determinants of the rate of nicotine metabolism and effects on smoking behavior
    Elaine Johnstone
    Department of Clinical Pharmacology, Cancer Research UK Medical Statistics Group, Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom
    Clin Pharmacol Ther 80:319-30. 2006
    ....
  3. ncbi Zyban for smoking cessation in a general practice setting: the response to an invitation to make a quit attempt
    Elaine Johnstone
    Cancer Research UK General Practice Research Group, Clinical Pharmacology, Oxford University, UK
    Addict Biol 9:227-32. 2004
    ..05). In conclusion, a real-world smoking cessation programme using Zyban with moderate support within a general practice setting may achieve satisfactory quit rates without widening existing disparities in cessation...
  4. ncbi The dopamine D2 receptor C32806T polymorphism (DRD2 Taq1A RFLP) exhibits no association with smoking behaviour in a healthy UK population
    E C Johnstone
    Cancer Research UK, General Practice Research Group, University of Oxford Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford, UK
    Addict Biol 9:221-6. 2004
    ..003) and age (p=0.002) but not with alcohol consumption (p=0.25) or DRD2 genotype (p=0.76)...
  5. ncbi Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch
    Elaine C Johnstone
    Cancer Research UK General Practice Research Group, Department of Clinical Pharmacology, University of Oxford, Oxford, UK
    Pharmacogenetics 14:83-90. 2004
    ..Our results support the need for further investigation into personalized therapies for smoking cessation based on individual genotype...
  6. doi Role of rare variants in undetermined multiple adenomatous polyposis and early-onset colorectal cancer
    Jeremie H Lefevre
    Department of Clinical Pharmacology, Cancer and Immunogenetics Laboratory, University of Oxford, Oxford, UK
    J Hum Genet 57:709-16. 2012
    ..2; 95% confidence interval=1.1-9.5; P=0.04). Rare variants are important risk factors in CRC and, as such, should be systematically assayed alongside common variation in the search for the genetic basis of complex diseases...
  7. pmc Weekly versus basic smoking cessation support in primary care: a randomised controlled trial
    Paul Aveyard
    Cancer Research UK General Practice Research Group, Department of Clinical Pharmacology, University of Oxford, Oxford, UK
    Thorax 62:898-903. 2007
    ....
  8. ncbi The genetic basis for smoking behavior: a systematic review and meta-analysis
    Marcus Munafo
    Department of Clinical Pharmacology, University of Oxford, UK
    Nicotine Tob Res 6:583-97. 2004
    ..Implications for the design of future studies are discussed, such as the need for the development of more specific phenotypes to increase the genetic signal in candidate gene studies...
  9. pmc Use of multivariate analysis to suggest a new molecular classification of colorectal cancer
    Enric Domingo
    Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, UK
    J Pathol 229:441-8. 2013
    ..Our classification also showed potentially improved prognostic capabilities, with group 3, and possibly group 1, independently predicting disease-free survival...
  10. pmc Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial
    Patricia Yudkin
    Department of Primary Health Care, University of Oxford, Oxford OX3 7LF
    BMJ 328:989-90. 2004
  11. pmc Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN
    Andrew D Beggs
    University of Oxford, Oxford, UK
    Oncotarget 3:1348-55. 2012
    ..015). For Ku70, further studies are required to investigate the potential relationship of non-homologous end joining with chromosomal instability. Loss of ATM expression might serve as a biomarker of poor prognosis in colorectal cancer...
  12. ncbi A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21
    Ian Tomlinson
    Molecular and Population Genetics Laboratory, Cancer Research UK, London WC2A 3PX, UK
    Nat Genet 39:984-8. 2007
    ..21, 95% c.i.: 1.10-1.34; P = 6.89 x 10(-5)). These data show that common, low-penetrance susceptibility alleles predispose to colorectal neoplasia...
  13. doi Cyclin D1 rare variants in UK multiple adenoma and early-onset colorectal cancer patients
    Carolina Bonilla
    Department of Clinical Pharmacology, University of Oxford, Headington, Oxford, UK
    J Hum Genet 56:58-63. 2011
    ..We conclude that rare variants of CCND1 are risk factors for colorectal cancer, with considerably larger effects than common polymorphisms, and as such should be systematically evaluated in susceptibility studies...
  14. pmc A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation
    Nicky J Welton
    Primary Care, Department, Community Based Medicine, University of Bristol, Bristol, UK
    Nicotine Tob Res 10:231-40. 2008
    ..In addition, single-gene tests are unlikely to be cost-effective, partly because the predictive value of these tests is likely to be modest...
  15. pmc Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial
    Elaine C Johnstone
    Department of Clinical Pharmacology, University of Oxford, Oxford, United Kingdom
    Cancer Epidemiol Biomarkers Prev 16:1065-9. 2007
    ....
  16. doi Genes and cigarette smoking
    Marcus R Munafo
    Department of Experimental Psychology, University of Bristol, Bristol, UK
    Addiction 103:893-904. 2008
    ..We also review future research horizons and the direction which studies of this kind are likely to take in the near future...
  17. pmc The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial
    Sean P David
    Center for Primary Care and Prevention, Brown Medical School Memorial Hospital of Rhode Island, Pawtucket, RI 02960, USA
    Nicotine Tob Res 9:225-31. 2007
    ....
  18. ncbi Smoking cessation, weight gain, and DRD4 -521 genotype
    Marcus R Munafo
    Department of Experimental Psychology, University of Bristol, Bristol, United Kingdom
    Am J Med Genet B Neuropsychiatr Genet 141:398-402. 2006
    ..Smoking cessation programmes should therefore consider incorporating follow-up support to promote weight loss among those who successfully stop smoking...
  19. ncbi Polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers: seeking confirmation of the association in a follow-up study
    Elaine C Johnstone
    Cancer Research UK General Practice Research Group, Institute of Health Sciences, Oxford, UK
    Pharmacogenetics 12:585-7. 2002
  20. ncbi Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1
    Matt J Neville
    Cancer Research UK General Practice Research Group, Department of Clinical Pharmacology, University of Oxford, Oxford, UK
    Hum Mutat 23:540-5. 2004
    ..If this is the case, then changes in ANKK1 activity may provide an alternative explanation for previously described associations between the DRD2 Taq1A RFLP and neuropsychiatric disorders such as addiction...
  21. ncbi Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping
    Robyn M Jacob
    Cancer Research UK General Practice Research Group, Department of Clinical Pharmacology, University of Oxford, Oxford, United Kingdom
    Clin Chem 50:1372-7. 2004
    ..The aim of the present study was to develop a reliable and robust assay for determining genotypic variants...
  22. ncbi Association between the serotonin transporter gene and alcohol consumption in social drinkers
    Marcus R Munafo
    Cancer Research UK General Practice Research Group, Department of Clinical Pharmacology, University of Oxford, Oxford, United Kingdom
    Am J Med Genet B Neuropsychiatr Genet 135:10-4. 2005
    ..Age at time of data collection and cigarette consumption were entered as covariates. These results replicate recent previous findings and suggest a possibility that this association may differ in men and women...
  23. ncbi Genetic testing: the future of smoking cessation therapy?
    Elaine C Johnstone
    ICRF General Practice Research Group, Institute of Health Sciences, Old Road, Oxford, OX3 7LF, UK
    Expert Rev Mol Diagn 2:60-8. 2002
    ....
  24. pmc A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans
    Sean P David
    Department of Clinical Pharmacology, Cancer Research United Kingdom General Practice Research Group, University of Oxford, Oxford OX2 6HE, United Kingdom
    J Neurosci 25:2586-90. 2005
    ..The results may offer a plausible physiological mechanism underlying the association between 5-HTTLPR genotype, behavioral traits, and mood states...
  25. ncbi Association of serotonin transporter genotype with selective processing of smoking-related stimuli in current smokers and ex-smokers
    Marcus R Munafo
    Department of Experimental Psychology, University of Bristol, United Kingdom
    Nicotine Tob Res 7:773-8. 2005
    ..086). Our data provide tentative support for a moderating influence of 5HTT genotype on attentional bias for smoking-related stimuli in ex-smokers. This finding may account for inconsistent reports of attentional bias among ex-smokers...
  26. ncbi Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial
    Marcus R Munafo
    Department of Experimental Psychology, University of Bristol, 8 Woodland Road, Bristol BS8 1TN, United Kingdom
    Cancer Epidemiol Biomarkers Prev 15:398-400. 2006
  27. ncbi Neuroticism mediates the association of the serotonin transporter gene with lifetime major depression
    Marcus R Munafo
    Department of Experimental Psychology, University of Bristol, Bristol, UK
    Neuropsychobiology 53:1-8. 2006
    ..We sought to address the question of whether trait neuroticism mediates the putative association between this polymorphism and lifetime major depression in adults drawn from the general population...
  28. doi Association of COMT Val108/158Met genotype with smoking cessation
    Marcus R Munafo
    Department of Experimental Psychology, University of Bristol, UK
    Pharmacogenet Genomics 18:121-8. 2008
    ..We also investigated the association of the COMT genotype with withdrawal and mood symptoms, to identify possible mediating mechanisms by which the COMT genotype might influence response to NRT...